Citadel Advisors’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$49.2M Buy
87,566
+69,723
+391% +$44.7M 0.01% 1381
2025
Q4
$12.1M Sell
17,843
-9,733
-35% -$6.63M ﹤0.01% 3008
2025
Q3
$17.6M Sell
27,576
-15,806
-36% -$9.59M ﹤0.01% 2494
2025
Q2
$23.3M Buy
43,382
+42,310
+3,947% +$20.2M ﹤0.01% 1969
2025
Q1
$450K Sell
1,072
-76,982
-99% -$33.4M ﹤0.01% 8709
2024
Q4
$32.3M Buy
78,054
+54,954
+238% +$24.1M 0.01% 1676
2024
Q3
$11.7M Sell
23,100
-54,272
-70% -$26.4M ﹤0.01% 2679
2024
Q2
$37.7M Buy
77,372
+35,125
+83% +$17.6M 0.01% 1384
2024
Q1
$22.8M Sell
42,247
-99,625
-70% -$54.4M ﹤0.01% 1938
2023
Q4
$78.7M Buy
141,872
+96,605
+213% +$45.4M 0.02% 838
2023
Q3
$19.8M Sell
45,267
-57,667
-56% -$28.8M ﹤0.01% 1875
2023
Q2
$51.7M Sell
102,934
-608,965
-86% -$292M 0.01% 1021
2023
Q1
$356M Buy
711,899
+313,801
+79% +$150M 0.08% 158
2022
Q4
$162M Buy
398,098
+29,767
+8% +$11.6M 0.04% 416
2022
Q3
$120M Buy
368,331
+264,023
+253% +$97M 0.03% 515
2022
Q2
$36.6M Buy
104,308
+102,533
+5,777% +$41.8M 0.01% 1283
2022
Q1
$971K Sell
1,775
-327
-16% -$172K ﹤0.01% 7760
2021
Q4
$1.38M Sell
2,102
-45,973
-96% -$28.9M ﹤0.01% 7072
2021
Q3
$29.9M Buy
+48,075
New +$32.3M 0.01% 1569
2021
Q2
Sell
-24,643
Closed -$13.6M 14004
2021
Q1
$12.1M Sell
24,643
-7,009
-22% -$3.51M ﹤0.01% 2700
2020
Q4
$15.8M Sell
31,652
-150,908
-83% -$67.5M ﹤0.01% 2062
2020
Q3
$71.8M Buy
182,560
+173,899
+2,008% +$64.3M 0.02% 641
2020
Q2
$2.86M Buy
8,661
+4,930
+132% +$1.43M ﹤0.01% 3945
2020
Q1
$904K Buy
+3,731
New +$974K ﹤0.01% 5524
2019
Q3
Sell
-5,738
Closed -$1.6M 9440
2019
Q2
$1.58M Buy
+5,738
New +$1.41M ﹤0.01% 4927
2019
Q1
Sell
-28,328
Closed -$5.85M 9548
2018
Q4
$5.27M Buy
28,328
+11,301
+66% +$2.32M ﹤0.01% 2706
2018
Q3
$4.25M Sell
17,027
-7,022
-29% -$1.7M ﹤0.01% 3209
2018
Q2
$5.24M Sell
24,049
-55,446
-70% -$11.4M ﹤0.01% 2706
2018
Q1
$15.2M Buy
79,495
+34,182
+75% +$6.31M 0.01% 1347
2017
Q4
$7.09M Buy
45,313
+40,562
+854% +$6.38M ﹤0.01% 2074
2017
Q3
$739K Sell
4,751
-59,502
-93% -$9.41M ﹤0.01% 4761
2017
Q2
$10.4M Buy
+64,253
New +$10.4M 0.01% 1432
2017
Q1
Sell
-35,893
Closed -$4.95M 7714
2016
Q4
$4.21M Sell
35,893
-7,726
-18% -$882K ﹤0.01% 2169
2016
Q3
$4.92M Buy
43,619
+38,420
+739% +$4.05M ﹤0.01% 2005
2016
Q2
$483K Sell
5,199
-61,705
-92% -$5.3M ﹤0.01% 4528
2016
Q1
$5.24M Sell
66,904
-2,751
-4% -$198K 0.01% 1722
2015
Q4
$5.08M Sell
69,655
-137,555
-66% -$9.81M 0.01% 1806
2015
Q3
$15.4M Buy
207,210
+22,768
+12% +$1.63M 0.01% 1070
2015
Q2
$11.8M Buy
184,442
+2,924
+2% +$202K 0.01% 1359
2015
Q1
$14M Sell
181,518
-532,846
-75% -$41.5M 0.01% 1203
2014
Q4
$53M Buy
714,364
+652,004
+1,046% +$45.7M 0.05% 447
2014
Q3
$3.67M Buy
62,360
+47,800
+328% +$3.02M ﹤0.01% 2262
2014
Q2
$972K Sell
14,560
-48,058
-77% -$3.06M ﹤0.01% 3525
2014
Q1
$3.8M Sell
62,618
-9,452
-13% -$563K ﹤0.01% 2015
2013
Q4
$3.83M Buy
72,070
+36,406
+102% +$1.92M 0.01% 1896
2013
Q3
$1.78M Sell
35,664
-203,540
-85% -$9.78M ﹤0.01% 2523
2013
Q2
$10.7M Buy
+239,204
New +$10.5M 0.02% 1025

Other funds holding IDXX

Citadel Advisors's IDXX Position: Q1 2026 in Review

Citadel Advisors increased its Idexx Laboratories (IDXX) stake by 391% in Q1 2026, buying an estimated $44.7M and bringing the position to 87,566 shares worth $49.2M. The position accounts for 0.01% of the portfolio, ranked #1381.

Citadel Advisors first reported a position in IDXX in Q2 2013 and has held it in 47 quarters since. The position peaked at $356M in Q1 2023. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Citadel Advisors held 87,566 shares of Idexx Laboratories worth $49.2M as of Q1 2026.
  • Citadel Advisors bought 69,723 Idexx Laboratories shares in Q1 2026, an estimated $44.7M.
  • Idexx Laboratories made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1381 holding.
  • Citadel Advisors first reported a position in Idexx Laboratories in Q2 2013 and has held it in 47 quarters since.
  • Citadel Advisors's Idexx Laboratories position peaked at $356M in Q1 2023.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.